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Objective:
Proton pump inhibitors (PPIs) and histamine H2 receptor antagonists (H2RA) rank in the top 5%
of Kentucky Medicaid drug expenditures. These two classes of drugs are used to treat duodenal ulcer,
gastric ulcer, gastroesophageal reflux disease (GERD), active benign ulcer, and erosive esophagitis. They
can also be used to treat heartburn, acid indigestion, and sour stomach. The FDA approved labeling for
these medications recommend use for no longer than 8 weeks; however, a review of the literature shows
that many patients take these classes of medications for much longer periods of time. There are also
increasing concerns about the adverse effects (e.g., hip fractures) associated with these medications,
especially the PPIs. An article featured in the Wall Street Journal (WSJ) on May 11th 2010 reported that
more than 119 million prescriptions were written for PPIs in the U.S. in 2009 and some doctors believe
these medications are over-prescribed for less severe ailments like indigestion or upset stomach.

The fact is that nearly everyone has seen commercials about heartburn and most people have
experience with this condition. These agents are being consumed in large amounts and those who use
them are probably unaware of the potential risk they are taking. Consumers have been led to believe for
nearly two decades that these are ‘benign’ drugs although several studies have shown these medications
are linked to infections, drug interactions, fracture and unnecessary drug expenditure. The Kentucky
Medicaid spending is rising at twice the rate of the budget, hence a protocol (for example regarding
length of therapy, or which patients are appropriate candidates for therapy) may help reduce
expenditures for these medications and thus reduce the budget gap. The objective of this study is to
determine the incidence of hip fracture associated with proton pump inhibitor (PPI) and/or H2 receptor
antagonist use in the Kentucky Medicaid population and to determine the total expenditures associated
with treating these hip fractures.

Background:

The advent of medications such as proton pump inhibitors (PPI) and H2 receptor antagonists
(H2RA) have changed and revolutionized the management of acid-related diseases such as
gastroesophageal reflux disease (GERD).There has been a great deal of interest in acid-suppressing
medications because they are among the most commonly prescribed medications1 in the United States.
In fact global pharmaceutical sales for acid-suppressing therapies exceeded $24 billion dollars in 2006.1

These agents carry an FDA labeled indication for short-term (4-8 weeks) therapy of duodenal
ulcer, gastric ulcer, gastroesophageal reflux disease (GERD), active benign ulcer, and erosive esophagitis.
In treatment of heartburn, acid indigestion, and sour stomach, the labeled indication is for 14 days of
therapy, then repeat treatment after 4 months if needed2. Since most patients take these medications
for periods greater than their indication21, there have been several reports about adverse effects
associated with chronic use, one of them being hip fractures. Hip fractures are a major cause of
morbidity and mortality; more than 329,000 persons are hospitalized annually with hip fractures in the
United States and the mortality rate is 5-10% after one month and about 30% after one year3. The
incidence and the economic consequences of hip fracture are substantial. Hence, the Kentucky Medicaid
program may be able to institute some policies to control the use of these agents.
The table below shows the total drug expenditure of Kentucky Medicaid for PPIs and H2RAs and
the cost associated with medical procedures for hip surgery from 2004 to 2009 (included in the drug
costs are individuals’ out-of-pocket payments and Medicaid costs; included in the hip surgery costs are
individuals’ out-of-pocket costs, Passport costs, Medicare and Medicaid costs) 4. In other words, Kentucky
Medicaid spends considerable tax dollars on the use of PPIs and H2RAs, hence if there is a causal effect
between these medications and hip fracture, Medicaid should be encouraged to adopt a policy to ensure
they are used appropriately thereby limiting Medicaid recipients’ risk for these potentially costly adverse
effects.

Table 1: Drug expenditure of Kentucky Medicaid for PPIs and H2RAs and medical procedures costs for hip
fracture (2004-2009)
Year

Total Spent (PPIs) [$]

Total Spent (H2RAs) [$]

Hip Fracture cost [$]

2004

23,219,922

10,964,607

1,004,198

2005

22,405,920

6,638,345

956,855

2006

12,601,746

3,449,352

981,494

2007

13,804,347

3,059,668

1,015,387

2008

18,253,050

2,600,807

936,601

2009

28,620,537

2,027,572

886,589

H2 receptor antagonists (H2RA) and PPIs effectively raise gastric pH. PPIs suppress acid secretion
by gastric parietal cells which results in the inhibition of acid secretion from all physiologic stimuli.5 H2
receptor antagonists inhibit histamine stimulated acid secretion. H2 receptors may be upregulated by H2
receptor antagonist, which can result in tolerance over time.6 Tolerance has not been shown with PPIs.5
Several recent studies in human volunteers have suggested that short-term use of acid suppressing
medications can decrease calcium absorption 7-9, which may lead to calcium deficiency. Since calcium
absorption is reduced in individuals taking acid suppression medications, the question arises about the
long-term “maintenance” use of these therapies and the risk of bone fractures or osteoporosis.
Decreased calcium absorption has been linked to increased risk of fracture, especially among older
women with low calcium intake10, 11.
Some H2 receptor antagonists (H2RA) and PPIs can be found over-the-counter (OTC) and hence
are easily accessible. As more patients self-medicate without consulting their physician and pharmacist,
it further worsens the problems associated with the adverse effects and costs associated with these
drugs.
In May 2010, the U.S Food and Drug Administration issued a warning about the use of PPIs and
increased risk of bone fractures. The greatest risk for these fractures (hip, wrist and spine) were in
patients who received high doses or used them for greater than 1 year. The majority of the patients in
the epidemiologic studies were greater than 50 years of age with the risk of fractures being limited to
this age group. To date, no randomized clinical trials of acid suppressing therapies have found an
increased risk of hip, wrist or spine fractures.
Literature review:
A summary of the epidemiological studies that have evaluated fracture risk with PPIs and H2RAs
use is presented in Table 2 below.
A retrospective case control study by Corley et al. 12 revealed that patients with hip fractures
were more likely than controls to have previously received a greater than 2-year supply of PPIs or H2RA,
odds ratio (OR) = 1.30 (95% CI, 1.21-1.39). Corley and colleagues concluded that use of drugs that inhibit
gastric acid is associated with an increased risk of hip fracture; however, the association was only found
among persons with at least one other risk factor for hip fracture. This study did not consider alcohol
use, diet, physical activity, body mass index, smoking histories of the patients hence there is a possibility

of bias. In addition, some members who took over-the-counter PPIs and H2RAs may be classified as
“unexposed” hence decreasing the strength of the association.
Another study by Yang et al. 13 concluded that there is an increased risk of hip fracture for PPI
use greater than 1 year; adjusted odds ratio (aOR) = 1.44 (95% CI, 1.30–1.59). The risk of hip fracture
increased with a high dose (>1.75 doses/day); aOR = 2.65 (95% CI, 1.80-3.90). The risk of hip fracture
also increased with longer duration of PPI use: 1 year, aOR = 1.22 (95% CI, 1.15-1.30) and 4 year, aOR =
1.59 (95% CI, 1.39-1.80). Some of the limitations in this study were incomplete information about the
BMI of 33% of the patients, inability to determine prior PPI use of patients enrolled in the database;
hence there could have been an underestimation of the duration of exposure. There was no information
on OTC calcium supplement use.
Vestergaard et al. 14 reported that use of PPIs was associated with an increased risk of fracture
within the last year (OR =1.18, 95% CI, 1.12-1.43) but no dose-response or duration-response
relationships were present. H2RAs were associated with a decreased fracture risk if they had been used
within the last year (OR = 0.88, 95% CI 0.82-0.95). During the study period, PPIs were available only on
prescription and H2RAs were available as OTC. Hence this introduces a bias because the database does
not contain information on drugs sold OTC. This may have underestimated the risk associated with these
drugs.
Targownik et al. 15 used a Canadian administrative claim database to determine if the use of PPIs
has any association with an increased risk of hip fracture. They also explored if there is a relationship
between duration of exposure to PPIs and osteoporosis-related fractures. They concluded that an
exposure of 7 or more years was associated with increased risk of an osteoporosis-related fracture
(adjusted OR 1.92, 95% CI, 1.16-3.16, p= 0.011). There was also an increased risk of hip fracture after 5
or more years of exposure (adjusted OR 1.62, 95% CI1.02-2.58, p= 0.04). The study has some limitations
such as lack of information about OTC calcium supplements, vitamin D supplements, tobacco and
alcohol use.
Kaye et al. 16 estimated the relative risk of hip fracture associated with proton pump inhibitor
(PPI) use in a population without major risk factors. This study was a 2-phase study. In phase 1, 4414
case patients (aged 50-79 yrs) with an incident hip fracture and at least 2 years of recorded history in
the database were analyzed. Phase 2 (a sub population of phase 1) included 1098 case patients

identified as having no major medical risks for hip fracture. The results indicated that the relative risk
(RR) for hip fracture among patients who received any PPI prescription was 0.9 (95% CI, 0.7–1.11)
compared with those with no PPI prescription. In other words, they found no evidence of an increased
risk of hip fracture with PPI use. One caveat for their research was that patients at risk for fracture were
excluded from the analysis.
Yu et al. 17 used dual-energy X-ray absorptiometry and assessed baseline use of proton pump
inhibitors (PPIs) and/or H2 receptor antagonists (H2RAs) in 5,755 men and 5,339 women. Medication
use and bone mineral density (BMD) were assessed, and hip and other nonspine fractures were
documented. On multivariate analysis, men using either PPIs or H2RAs had lower cross-sectional bone
mass. No significant BMD differences were observed among women. However, there was an increased
risk of nonspine fracture among women using PPIs (relative hazard [RH] = 1.34, 95% confidence interval
[CI] 1.10-1.64). PPI use was also associated with an increased risk of nonspine fracture in men but only
among those who were not taking calcium supplements (RH = 1.49, 95% CI 1.04-2.14). H2RA use was not
associated with nonspine fractures, and neither H2RA use nor PPI use was associated with incident hip
fractures in men or women. The use of PPIs in older women, and perhaps older men with low calcium
intake, may be associated with a modestly increased risk of nonspine fracture.
Some of these studies have identified a possible correlation between acid suppressing therapies
and bone fracture. A major shortcoming is the possibility of residual confounders unidentified by the
administrative databases used to analyze this relationship. Some confounders are inability to track OTC
use of these medications, and the fact that some of these databases do not report tobacco and alcohol
use in the patients. These introduce a bias and decrease the validity and reliability of these studies.
Another issue is that these studies are retrospective in nature and there are no randomized clinical
studies that have been done to establish the relationship between the incidence of fracture and acid
suppressive therapy use.
Methodology:
This is a retrospective case-control study of pharmacy and medical claims from the Kentucky
Medicaid database of patients on acid suppressing therapy with an incident diagnosis of hip fracture
(ICD-9-CM) codes 820.0 to 821.20 (hip or femur fractures) between January 1, 2000 and December 31,
2009. The index date is the fracture date. Enrollment in Medicaid has to be continuous at least 18

months prior to the index date. For each case, matched controls were randomly selected from the
Kentucky Medicaid Database. Controls were chosen from among eligible adult members who lacked a
diagnosis of a hip fracture at the index date of the matched case. The controls also had 18 months of
continuous membership before the index date. Pharmacy data were identified using the National Drug
Code (NDC). Included in the pharmacy data were the drug dispensed, date the drug was dispensed, the
frequency of refills, directions for use and amount paid. Medical claims were identified by using the
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. Included
in the medical claims data were date of service, and amount paid. In addition, data were available for
age, gender, and plan enrollment time for each patient.
For comparisons of proportions, chi-square statistics were used. A conditional logistic regression
model was used to estimate the relative magnitude in relation to the use of PPIs and H2RAs. The
primary exposure for the analysis is acid suppressing therapy of more than one year before the index
date. The one year duration was used because alterations in fracture risk due to the use of other
medications, such as bisphosphonates, thiazide diuretics, and corticosteroids were apparent after 1 year
of exposure.18, 19 Medication adherences for potential confounders will be measured by medication
possession ratio (MPR). MPR of at least 80% is required for inclusion. Through retrospective drug claims
analysis, MPR looks at medication refill history over a period of time and calculates how many doses of
medication a patient obtained during the study period compared to how many doses should have been
obtained.20
The primary outcome of the study is to determine if there is an association between acid
inhibition and hip fractures. I also evaluated whether fracture risk is generally associated with other
commonly used medications, which may suggest confounding. The study will utilize standard analytic
techniques for evaluating case-control studies and conditional logistic regression. All definitions and
modeling strategies were planned a priori. All statistical analyses were performed at a significance level
of 0.05 in SAS statistical package version 9.2 SAS Institute Inc., Cary, North Carolina).

MPR20= Sum of days supply of drugs
[# of days between first and last
fill plus days’ supply of last fill]

Table 2: Epidemiological Studies Evaluating Fracture Risk with Proton Pump Inhibitors (PPIs)
Study
 Vestergaard
2006

Study time period
1/1/2000 –
12/31/2000

Study population




 Yang 2006

1987 - 2003






 Targownik 2008

1996 – 2004






124,655 cases with
fractures
373,962 matched
controls
All ages Data
source: Denmark
health database

Finding related to PPIs
PPI use within the last year






Overall fracture risk, Odds Ratio (OR) = 1.18 (95% CI, 1.12–1.43)
Risk of hip fracture, OR = 1.45 (95% CI, 1.28–1.65)
Risk of spine fracture, OR = 1.60 (95% CI, 1.25–2.04)
Risk of forearm fracture, OR = 0.95 (0.82-1.11)
No dose-response relationship seen with PPIs and fracture risk:
(DDD [defined daily doses] were the number of doses in a year)

13,556 cases with
fractures
135,386 matched
controls
Ages ≥ 50 years
Data source:
U.K./GPRD



Risk of hip fracture, PPI use > 1 year
adjusted Odds Ratio (aOR)± = 1.44 (95% CI, 1.30–1.59)
Risk of hip fracture increased with high-dose PPI use > 1 year:
(dose defined as dose/day, >1.75 doses/day)
aOR = 2.65 (95% CI, 1.80-3.90)
Risk of hip fracture increased with longer duration of PPI use
o 1 yr, aOR = 1.22 (95% CI, 1.15-1.30)
o 4 yr, aOR = 1.59 (95% CI, 1.39-1.80)

15,792 cases with
fractures
47,289 matched
controls
Ages ≥ 50 years
Data source:
PHRDR/ Manitoba,
Canada









Risk of hip, wrist, spine fractures with PPI use ≥ 7 years
adjusted Odds Ratio (aOR) ¥ = 1.92 (95% CI, 1.16–3.18)
Risk of hip fracture increased with longer duration of use
o PPI use ≥ 5 years, aOR = 1.62 (95% CI, 1.02–2.58)
o PPI use ≥ 6 years, aOR = 2.49 (95% CI, 1.33-4.67)
o PPI use ≥ 7 years, aOR = 4.55 (95% CI, 1.68–12.29)

 Kaye 2008

1995 - 2005






 Corley 2010

1995-2007






1,098 cases with
fractures
10,923 matched
controls
Ages 50 – 70
years
Data source:
U.K/GPRD



33,752 cases with
fractures
130,471 matched
controls
Ages ≥ 18 years
Data source:
KPNC/ California,
USA









 Yu 2008

Women: 7.6 years
mean follow-up



Men: 5.6 years
mean follow-up





Women (4,574
non-PPI users and
234 PPI users)
Men (4,920 nonPPI users and 487
PPI users) Ages ≥
65 years
Data source:





Estimated Relative Risk (RR) of hip fracture = 0.9 (95% CI, 0.7–1.11)
(Patients at risk for fracture were excluded from the analysis)
Risk of hip fracture not detected with increased number of PPI
prescriptions

Risk of fracture with ≥ 2 years of PPI use and 1 other risk factor
Odds Ratio (OR) = 1.30 (95% CI, 1.21–1.39)
o Risk factors: alcohol abuse, arthritis, diabetes, kidney disease,
glucocorticoids, cerebrovascular disease, dementia, epilepsy,
gait disorder, hemiplegia, psychoses, smoking, visual
impairment, anxiolytic use
Risk of fracture increased with higher PPI dose:
(dose = number of pills per day >1.5)
OR = 1.41 (95% CI, 1.21-1.64)
Risk of fracture did not consistently increase with longer duration of use

Risk of hip fracture
o Women: adjusted Relative Hazard (aRH)= 1.16 (95% CI, 0.801.67)
o Men: aRH = 0.62 (95% CI, 0.26-1.44)
Risk of nonspine fracture
o Women: aRH = 1.34 (95% CI, 1.10-1.64)
o Men: aRH = 1.21 (95% CI, 0.91-1.62)

MrOS/SOF
 Gray 2010

7.8 years, mean
follow-up







2,831 PPIs users
127,756 non-PPIs
users
Post-menopausal
women ages 50 –
79 years
Data source: WHI
OS/WHI CT







Risk of total fractures
adjusted Hazard Ratio (aHR) ≠ = 1.25 (95% CI, 1.15-1.36)
Risk of hip fracture, aHR = 1.00 (95% CI, 0.71-1.40)
Risk of spine fracture, aHR = 1.47 (95% CI, 1.18-1.82)
Risk of wrist fracture, aHR = 1.26 (95% CI, 1.05-1.51)
No consistent trend for fracture risk with duration of use

Results:
Table 3 shows baseline characteristics of the hip fracture cases and controls. There were

500,910 patients without hip fracture and 2,634 patients with hip fracture; hence the baseline
characteristics for the two populations were significantly different. The fracture cases more often
were females. Fracture cases were prominent in individuals greater than 50 years and also residents
of rural area. The comorbidity and use of drugs in general were higher among cases than controls.
Hip fracture cases were also significantly more likely to have a medical diagnosis that had known
associations with either hip fracture or the risk of falling which is consistent with findings from
previous studies.13, 15
Table 3: Characteristics of hip fracture cases and controls
Variable
Gender
Male
Female
Region
Urban
Rural
Age
≥50
<50
Race
Black
White
Other
Medication use
Thiazide
Corticosteroid
Estrogen
Antiparkinsonian
Antidepressants
NSAIDS
Statin
Thyroid
Bisphosphonates
Anticoagulants

Cases (n = 2,634)

Controls (n = 500,910)

Adjusted OR (95% CI)

685 (26.01)
1,949 (73.99)

187,836 (37.50)
313,074 (62.50)

0.63 (0.58–0.69)
Reference

1,010 (38.34)
1,624 (61.66)

196,196 (39.17)
304,714 (60.34)

1.06 (0.98–1.16)
Reference

2,157 (81.89)
477 (18.11)

199,913 (39.91)
300,997 (60.09)

3.92 (3.51–4.37)
Reference

178 (6.76)
2,308 (87.62)
148 (5.62)

55,177 (11.02)
416,844 (83.22)
28,889 (5.77)

0.72 (0.61-0.84)
Reference
0.75 (0.63–0.89)

363 (13.78)
51 (1.94)
26 (0.99)
93 (3.53)
817 (31.02)
547 (20.77)
54 (2.05)
243 (9.23)
55 (2.09)
207 (7.86)

48,842 (9.75)
5,192 (1.04)
6,482 (1.99)
8,755 (1.75)
150,314 (30.01)
163,194 (32.58)
10,830 (2.16)
26,236 (5.24)
2,161 (0.43)
13.632 (2.72)

0.79 (0.70–0.89)
0.79 (0.59–1.05)
0.53 (0.36–0.78)
1.11 (0.90–1.37)
0.64 (0.58–0.70)
0.71 (0.64–0.79)
0.83 (0.72–0.97)
0.47 (0.36–0.62)
1.84 (1.40–2.43)
1.17 (1.00–1.36)

Calcitonin
Sedatives
Health Condition
Arthritis
Cerebrovascular disease
Hemiplegia
Asthma
Dementia psychoses
Diabetes Mellitus
Thyroid disease
Ischemic Heart Disease
Epilepsy
Gait disorder
Peptic ulcer disease
GERD
Visual Impairment
Chronic kidney disease
Charlson Index
0
1

90 (3.42)
779 (29.57)

5,107 (1.02)
88,367 (17.64)

1.12 (0.90–1.39)
1.36 (1.24–1.49)

15 (0.57)
453 (17.20)
15 (0.57)
159 (6.04)
595 (22.59)
673 (25.55)
156 (5.92)
450 (17.07)
85 (3.23)
123 (4.67)
38 (1.44)
176 (6.68)
743 (28.21)
135 (5.13)

1,256 (0.25)
22,890 (4.57)
1,214 (0.24)
28,197 (5.63)
66,652 (13.31)
56,174 (11.21)
18,938 (3.78)
36,585 (7.30)
8.017 (1.60)
4,871 (0.97)
3.812 (0.76)
24,176 (4.83)
120,756 (24.11)
6,196 (1.24)

1.38 (0.82–2.31)
1.36 (1.21–1.52)
0.81 (0.48–1.36)
0.78 (0.66–0.93)
1.53 (1.39–1.69)
1.05 (0.95–1.16)
1.15 (0.96–1.38)
1.04 (0.93–1.16)
1.94 (1.55–2.43)
2.23 (1.84–2.70)
0.88 (0.63–1.21)
0.83 (0.71–0.97)
1.07 (0.98–1.17)
1.73 (1.45–2.08)

1,014 (38.50)
1,620 (61.50)

361,866 (72.24)
139,044 (27.76)

Reference
2.07 (1.87–2.29)

The relationship between use of PPIs, H2RAs and hip fractures is shown in Table 4. An MPR greater than
80% for PPIs and H2RAs use was statistically significantly associated with an increased OR for hip
fracture. The multivariable adjusted OR for all potential confounders for hip fracture associated with PPI
and H2RA therapies with more than one year use was 2.08 (95% CI, 1.85-2.34; P<.0001) and 3.08 (95%
CI, 2.77-3.44; P<.0001) respectively.

Table 4. Association between PPIs and H2RAs Use and Hip Fracture Risk in a Population-Based CaseControl Study
Variable
PPI ≥ 80% MPR
PPI < 80% MPR
H2RA ≥ 80% MPR
H2RA < 80% MPR

Cases (n = 2,634)
420 (15.95)
2,214 (84.05)
485 (18.41)
2,149 (81.59)

Controls (n = 500,910)
29,514 (5.89)
471,396 (94.11)
24,194 (4.83)
476,716 (95.17)

Adjusted OR (95% CI)
2.08 (1.85–2.34)
Reference
3.08 (2.77–3.44)
Reference

Discussion:
In this population-based case-control study, I found a significant relationship between use of
PPIs and H2RAs and the risk of hip fracture after controlling for potential confounders. This finding is
consistent with previous studies. 12, 13, 14, 15 The risk of hip fracture was higher among subjects taking
H2RAs compared with PPI. This is counterintuitive because PPIs are more potent acid suppressing
therapy in comparison to H2RAs. Overall, the increased risk was confined to persons with certain other
risk factors for hip fracture.
There are several mechanisms by which acid suppressing therapies may increase hip fracture
risks. The increased risk may be as a result of a decrease in calcium absorption. An acidic environment in
the gastrointestinal tract facilitates the release of ionized calcium from insoluble calcium salts22.
One of the strengths of this study was the use of a computerized database allowing for a largescale population-based design and the use of data on exposure and confounders that are collected
before the date of fracture. Thus recall bias did not influence data collection.
There are several potential limitations of this study; a number of possible confounding variables,
including body mass index, physical activity, smoking, alcohol use, sun exposure and over-the-counter
use of calcium/vitamin D supplements, which are associated with fracture were not available in the
database. In addition some of the PPIs and H2RAs are over-the-counter (OTC) medications; hence some
patients who took these OTC medications may have been classified as controls, which would have
expected to decrease the strength of the association.
In summary, results of this study suggest that there is a significant relationship between PPIs
and H2RAs use and hip fracture risk. Prospective randomized trial clinical studies are necessary to
confirm my findings and an experimental study on the mechanism by which PPIs and H2RAs may
increase hip fracture risk is necessary.

Recommendations:

A policy on appropriate acid-suppressing therapy use might be mandated by the Kentucky
Medicaid program. This policy will essentially reduce cost by eliminating millions of dollars spent on
unnecessary drug expenditure, thus closing the budget gap in Kentucky Medicaid program. The policy
should be in accordance with the FDA approved labeling of this class of drug. Some policies that may
improve appropriate use of these agents are:

1. Prior authorization protocol for patients taking this medication for more than 8 weeks. A
requirement for endoscopic diagnosis should be mandated beyond 8 weeks.
2. Moving this drug class behind the counter just like pseudoephedrine containing products but
not electronically monitoring these products. This will create an opportunity for patients to have
a conversation with the pharmacist about appropriate drug use and most especially non-drug
measures they can implement in avoiding heartburn and acid reflux.
3. When prescribing these agents, consider whether a lower dose or shorter duration of
therapy would adequately treat the patient's condition.
4. Individuals at risk for osteoporosis should have their bone status managed according to current
clinical practice, and should take adequate vitamin D and calcium supplementation.

Lifestyle changes should be advocated in order to reduce symptoms of GERD. These changes could be:

1. Avoid heart-burn triggering food such as orange juice, chocolate, tomato sauce, spicy foods,
mint, garlic, and vinegar. These may vary from person to person.
2. Staying upright for a few hours after eating and abstaining from exercise after right after eating
3. Eating smaller meals, reducing caffeine and alcohol intake and avoiding cigarettes.
4. Weight loss and incorporating physical activity.
5. Wear looser-fitted clothes.
6. Bending with your knees instead bending over at the waist.
7. Elevate head of the bed.

Appendix
Passport is a health care plan that uses federal and state funds, through a Medicaid waiver, to pay for
in-home alternatives to nursing home care for low-income, Medicaid eligible seniors.

CPT codes used to determine the cost of hip fracture surgeries are: 27193, 27194, 27200, 27202, 27215,
27216, 27217, 27218, 27220, 27222, 27226, 27227, 27228, 27230, 27232, 27235, 27236, 27238, 27240,
27244, 27245, 27246, 27248, 27250, 27252, 27253, 27254, 27256, 27257, 27258, 27259, 27265, 27266,
27267, 27268, and 27269.

NDC is a unique 10 digit, 3-segment numeric identifier assigned to each medication intended for human
use in the United States.
ICD-9-CM is used to code and classify morbidity data from the inpatient and outpatient records,
physician offices, and most National Center for Health Statistics (NCHS) surveys.
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